| References |
1. Flanagan EP, Cabre P, Weinshenker BG, Sauver JS, Jacobson DJ, Majed M, Lennon VA, Lucchinetti CF, McKeon A, Matiello M, Kale N, Wingerchuk DM, Mandrekar J, Sagen JA, Fryer JP, Robinson AB, Pittock SJ. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol 2016;79 (5): 775-783. 2. Hor JY, Asgari N, Nakashima I, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence world- wide. Front Neurol. 2020;11:501. 3. Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica. Nat Rev Dis Primers. 2020 Oct 22;6(1):85. 4. Tan, K, Yeo, T, Yong, KP, et al. Central nervous system inflammatory demyelinating diseases and neuroimmunology in Singapore-Epidemiology and evolution of an emerging subspecialty. Neurol Clin Neurosci. 2021; 9: 259- 265 5. Bukhari W, Prain KM, et al. Incidence and prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):632-638 6. Siantar RG, Ibrahim FNI, Htoon HM, Tow SLC, Goh KY, Loo JL, Lim SA, Milea D, Tien MCH, Chen Z, Yeo T, Chai JYH, Singhal S, Chin CF, Tan K. Should Aquaporin-4 Antibody Test Be Performed in all Patients With Isolated Optic Neuritis? J Neuroophthalmol. 2022 Oct 18. 7. Foo R, Yau C, Singhal S, Tow S, Loo JL, Tan K, Milea D. Optic Neuritis in the Era of NMOSD and MOGAD: A Survey of Practice Patterns in Singapore. Asia Pac J Ophthalmol (Phila). 2022 Mar-Apr 01;11(2):184- 195. 8. Yamagami A, Wakakura M, Inoue K, Ishikawa H, Takahashi T, Tanaka K. Clinical Characteristics of Anti- aquaporin 4 Antibody Positive Optic Neuritis in Japan. Neuroophthalmology. 2018 Oct 9;43(2):71-80 9. Soares-Dos-Reis R, Tsz-Ching JL, Kim SH, Jacob A, Whittam D, Berthelot E, Paul F, Nakashima I, Tye JSN, De Seze J, Jitprapaikulsan J, Tan K, Yang L, Elsone L, Leite MI, Mealy MA, Levy M, Fan M, Siebert N, Asgari N, Cabre P, Siritho S, Pittock SJ, Wing-Ho SC, Senger T, Yeo T, Takai Y, Pandit L, Kim HJ, Palace J. Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence. Mult Scler Relat Disord. 2021 Aug;53:103080 10. Tisavipat N, Lapanakoakiat S, Siengwattana P, Rattanathamsakul N, Jitprapaikulsan J, Prayoonwiwat N, Siritho S. A quarter-century report on neuromyelitis optica spectrum disorder in Thailand: A single- center tertiary care cohort. Mult Scler Relat Disord. 2022 Jul;63:103907 11. Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020 Apr;19(4):298-306. 12. Senanayake B, Aravinthan M, Weerasinghe S. Clinical characteristics, sero- prevalence, treatment and outcomes of AQP4 IgG associated neuromyelits optic spectrum disorder (NMOSD) in Sri Lanka. Mult Scler Relat Disord. 2022 Mar;59:103663 |
